Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.Analysts called the stock reaction overdone, while Chief Executive Vlad Coric ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...

Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its ...

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Acelyrin rejected a bid by Concentra and Atara cut staff.

Bernstein lowered the firm’s price target on Biohaven (BHVN) to $57 from $73 and keeps an Outperform rating on the shares. The firm notes the ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. | Biohaven’s bipolar ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...

Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained ...

Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...